Literature DB >> 26793323

Pharmacokinetic profile evaluation of di-μ-hydroxo-bis(quercetinatooxovanadium(IV)) complex.

B S Velescu1, Valentina Uivarosi1, Anca Buzescu1, I Sarbu1, Ecaterina Ionescu2, Valentina Anuta1.   

Abstract

The present study was designed to evaluate the pharmacokinetic (PK) properties of di-μ-hydroxo-bis(quercetinatooxovanadium(IV) (HOBQOV) complex, with hypoglycemic and hypolipidemic properties, in rats after a single i.p. dose of 100 mg/kg b.w. The HOBQOV complex pharmacokinetics is described by a bicompartmental model and the plasma concentration decrease is described by two phases that might be correlated to the distribution and elimination processes. The obtained results suggest a PK profile of the complex suitable for a profound distribution in the animal organism with possibility of interaction with the cytosolic enzymes.

Entities:  

Keywords:  HOBQOV; HPLC; bicompartmental model; pharmacokinetics

Year:  2014        PMID： 26793323      PMCID： PMC4709704          DOI： 10.12865/CHSJ.40.04.06

Source DB:  PubMed          Journal:  Curr Health Sci J


  6 in total

Review 1.  Metallo-allixinate complexes with anti-diabetic and anti-metabolic syndrome activities.

Authors:  Hiromu Sakurai; Akira Katoh; Tamas Kiss; Tamas Jakusch; Masakazu Hattori
Journal:  Metallomics       Date:  2010-09-13       Impact factor: 4.526

Review 2.  Metal-based anti-diabetic drugs: advances and challenges.

Authors:  Aviva Levina; Peter A Lay
Journal:  Dalton Trans       Date:  2011-07-13       Impact factor: 4.390

3.  Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats.

Authors:  H Sakurai; K Tsuchiya; M Nukatsuka; M Sofue; J Kawada
Journal:  J Endocrinol       Date:  1990-09       Impact factor: 4.286

Review 4.  Insulin-like effects of vanadium: basic and clinical implications.

Authors:  I Goldwaser; D Gefel; E Gershonov; M Fridkin; Y Shechter
Journal:  J Inorg Biochem       Date:  2000-05-30       Impact factor: 4.155

5.  Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.

Authors:  S Montilla; G Marchesini; A Sammarco; M P Trotta; P D Siviero; C Tomino; D Melchiorri; L Pani
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-10-06       Impact factor: 4.222

Review 6.  Vanadium treatment of type 2 diabetes: a view to the future.

Authors:  Katherine H Thompson; Jay Lichter; Carl LeBel; Michael C Scaife; John H McNeill; Chris Orvig
Journal:  J Inorg Biochem       Date:  2008-12-24       Impact factor: 4.155
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.